The Heart Of The Matter: Early Vs. Late QT Prolongation Testing
Source: Altasciences
The thorough and precise evaluation of cardiac effects is a critical element of new chemical entity development. You can choose to add early cardiac safety assessment to your first-in-human studies, or wait and perform a thorough QT prolongation study.
Dr. Beatrice Setnik, Altasciences' Chief Scientific Officer, walks through the differences between early and late QT prolongation testing.
access the Webinar!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Altasciences
This website uses cookies to ensure you get the best experience on our website. Learn more